Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sanofi's Dupixent misses sales estimates, Regeneron slips

Sanofi (Euronext:SAN; NYSE:SNY) reported 1Q18 earnings, including sales of atopic dermatitis drug Dupixent dupilumab that missed estimates.

The company's partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) slid $10.92 to $313.05 on the news Friday, shedding nearly $1.2 billion in market cap.

Sanofi said Dupixent, which it developed

Read the full 445 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers